Colchicine as an oral corticosteroid sparing agent for asthma

Abstract

Background: Oral corticosteroids are used as a treatment for asthma, but they are often associated with serious side effects. Colchicine is an anti-inflammatory, immuno modulating agent, which could potentially have a beneficial effect in the treatment of asthma as well as act as a steroid-sparing agent. Objectives: To determine the effectiveness of colchicine as an oral corticosteroid sparing agent for in the treatment of chronic asthma. Search methods: We searched the Cochrane Airways Group Specialised Register (to November 2009), SIGLE (1980 to 2001) and reference lists of potential articles. We also contacted researchers in the field. Selection criteria: Randomised controlled trials investigating the addition of colchicine compared to placebo in stable steroid dependent asthmatics. Data collection and analysis: No trials were found that met the inclusion criteria. Main results: We were unable to perform any meta-analyses. Two small studies have assessed the efficacy of colchicine subsequent to inhaled steroid withdrawal and as a tapering agent in inhaled steroids. Both studies failed to detect a significant difference between colchicine and placebo. An update search conducted in November 2009 did not identify any new trials. Authors' conclusions: No relevant trials have been published, so there is no evidence to indicate that colchicine is beneficial or otherwise in the management of steroid-dependent asthmatic patients. There is a need for well designed randomised controlled trials to be performed.